Salem Alshemmari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salem Alshemmari has a total of 432 co-authors. Here are the top co-authors by number of shared publications:
Abdulaziz Hamadah
Department of Hematology, Kuwait Cancer Control Center
5 shared publicationsAnita Kunhikrishnan
4 shared publicationsReem Ameen
Department of Medical Lab Sciences, Health Sciences Center, Jabriya, State of Kuwait
4 shared publicationsReshmi Rajan
Department of Hematology, Kuwait Cancer Control Center, Kuwait City, Kuwait
4 shared publications- Ahmad Alhuraiji
Department of Hematology, Kuwait Cancer Control Center
3 shared publications Mazyad Almazyad
Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait, Kuwait
3 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Wiley in HemaSphere
- Vol. 10 (11)
Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC
The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based combinations. In this retrospective multicenter study, data from 1720 patients were collected; 23.1% received venetoclax single agent and 76.9% venetoclax combinations (mostly containing anti‐CD20 monoclonal antibodies and/or BTK inhibitors). Combination regimens were used in 97.7% of treatment‐naïve (TN) patients and 65.8% of patients with relapsed/refractory (R/R) CLL. Preexisting AIC were reported in 11.7% of patients (8.7% in TN and 13.4% in R/R, P = 0.005). CLL‐related genetic risk factors and disease outcomes did not differ in patients with and without preexisting AIC. Irrespective of treatment type, venetoclax therapy resulted in AIC resolution or improvement in 63% of patients with active or controlled AIC. Treatment‐emergent AIC occurred in 2.6% of patients (2% in TN and 2.9% in R/R, not statistically significant). AIC episodes were reported in 4.3% of patients treated with venetoclax monotherapy and in 2.1% of those treated with venetoclax‐based combinations (P = 0.02). After standard management, AIC was considered resolved or controlled in 82% of the patients, with no substantial difference between treatment groups. Venetoclax‐based therapies have a beneficial impact on the outcome of CLL‐associated preexisting AIC. Treatment‐emergent AIC is a rare and generally manageable event. Although more frequent with venetoclax monotherapy in unadjusted analysis, this association was attenuated after adjustment for baseline prognostic factors.
- 6 November 2026
- Published by Wiley in HemaSphere
- Vol. 10 (11)
Open AccessImpact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC
The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based combinations. In this retrospective multicenter study, data from 1720 patients were collected; 23.1% received venetoclax single agent and 76.9% venetoclax combinations (mostly containing anti‐CD20 monoclonal antibodies and/or BTK inhibitors). Combination regimens were used in 97.7% of treatment‐naïve (TN) patients and 65.8% of patients with relapsed/refractory (R/R) CLL. Preexisting AIC were reported in 11.7% of patients (8.7% in TN and 13.4% in R/R, P = 0.005). CLL‐related genetic risk factors and disease outcomes did not differ in patients with and without preexisting AIC. Irrespective of treatment type, venetoclax therapy resulted in AIC resolution or improvement in 63% of patients with active or controlled AIC. Treatment‐emergent AIC occurred in 2.6% of patients (2% in TN and 2.9% in R/R, not statistically significant). AIC episodes were reported in 4.3% of patients treated with venetoclax monotherapy and in 2.1% of those treated with venetoclax‐based combinations (P = 0.02). After standard management, AIC was considered resolved or controlled in 82% of the patients, with no substantial difference between treatment groups. Venetoclax‐based therapies have a beneficial impact on the outcome of CLL‐associated preexisting AIC. Treatment‐emergent AIC is a rare and generally manageable event. Although more frequent with venetoclax monotherapy in unadjusted analysis, this association was attenuated after adjustment for baseline prognostic factors.
- Open Access
- 4 September 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (4)
Outcomes and clinical characteristics of acute promyelocytic leukemia in Kuwait: a 15-year national cohort study
- 4 September 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (4)
Open AccessOutcomes and clinical characteristics of acute promyelocytic leukemia in Kuwait: a 15-year national cohort study
- Open Access
- 2 April 2026
- Published by S. Karger AG in Medical Principles and Practice
- p. 1-11
Prevalence and Impact of Cardiovascular Comorbidities on Disease Outcomes in a Middle Eastern Chronic Lymphocytic Leukemia Population: A Retrospective Study at Kuwait Cancer Control Center
Objectives: We aimed to investigate the prevalence of comorbidities including diabetes mellitus (DM), hypertension, dyslipidemia, and cardiovascular disease in the Middle Eastern chronic lymphocytic leukemia (CLL) population and their correlation with disease outcome at the Kuwait Cancer Control Center (KCCC). Methods: We performed a retrospective study of the CLL patients diagnosed in the KCCC between 2008 and 2021. The hazards ratio (HR) of death was calculated using Cox regression analysis. Statistical analysis was performed using SPSS (v27). Results: A total of 316 patients had recorded comorbidities. The mean age at diagnosis was 60 years (SD + 13) with a male-to-female ratio of 3:1. Of these, 140 (44%) had hypertension, 132 (42%) had DM, and 32 (10%) had dyslipidemia. Nineteen CLL patients (6%) had vascular disease at diagnosis and 48 (15%) had a cardiac disease. The HR of death in patients with DM, hypertension, and dyslipidemia was 1.74 (1.04–2.89; p value 0.034), 1.14 (0.68–1.91; p value 0.628), and 1.91 (0.91–3.77; p value 0.063), respectively. The vascular disease and the cardiac disease were associated with HR of death of 3.48 (1.69–7.15; p value <0.001) and 1.39 (0.74–2.61; p value 0.312), respectively. In the multivariate analysis, vascular comorbidities remained as an independent predictor of death with an HR of 2.96 (1.41–6.21; p value = 0.004). Conclusion: The cardiovascular disease and associated risk factors are prevalent in the Kuwaiti CLL patients, and they are also associated with an unfavorable prognosis.
- 2 April 2026
- Published by S. Karger AG in Medical Principles and Practice
- p. 1-11
Open AccessPrevalence and Impact of Cardiovascular Comorbidities on Disease Outcomes in a Middle Eastern Chronic Lymphocytic Leukemia Population: A Retrospective Study at Kuwait Cancer Control Center
Objectives: We aimed to investigate the prevalence of comorbidities including diabetes mellitus (DM), hypertension, dyslipidemia, and cardiovascular disease in the Middle Eastern chronic lymphocytic leukemia (CLL) population and their correlation with disease outcome at the Kuwait Cancer Control Center (KCCC). Methods: We performed a retrospective study of the CLL patients diagnosed in the KCCC between 2008 and 2021. The hazards ratio (HR) of death was calculated using Cox regression analysis. Statistical analysis was performed using SPSS (v27). Results: A total of 316 patients had recorded comorbidities. The mean age at diagnosis was 60 years (SD + 13) with a male-to-female ratio of 3:1. Of these, 140 (44%) had hypertension, 132 (42%) had DM, and 32 (10%) had dyslipidemia. Nineteen CLL patients (6%) had vascular disease at diagnosis and 48 (15%) had a cardiac disease. The HR of death in patients with DM, hypertension, and dyslipidemia was 1.74 (1.04–2.89; p value 0.034), 1.14 (0.68–1.91; p value 0.628), and 1.91 (0.91–3.77; p value 0.063), respectively. The vascular disease and the cardiac disease were associated with HR of death of 3.48 (1.69–7.15; p value <0.001) and 1.39 (0.74–2.61; p value 0.312), respectively. In the multivariate analysis, vascular comorbidities remained as an independent predictor of death with an HR of 2.96 (1.41–6.21; p value = 0.004). Conclusion: The cardiovascular disease and associated risk factors are prevalent in the Kuwaiti CLL patients, and they are also associated with an unfavorable prognosis.
- 1 April 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (6) , 668-676
Twelve-year utilization and outcomes of haploidentical hematopoietic stem cell transplantation (HSCT) in the Eastern Mediterranean (EM) region: A multicenter EMBMT registry analysis
Haploidentical hematopoietic stem cell transplant (Haplo-HSCT) has emerged as an alternative for patients lacking matched human leukocyte antigen (HLA) donors. The scarcity of stem cell donor registries and cord banks across the Eastern Mediterranean (EM) region has led to increased need of Haplo-HSCT as a mean to overcome this limitation. In this study, we aimed to assess trends in Haplo-HSCT utilization within the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) registry from 2012 to 2024, and describe key clinical and transplant-related factors associated with patient outcomes. We conducted a retrospective, multicenter registry-based analysis of patients who had their first un-manipulated Haplo-HSCT in ten EMBMT centers across six countries, who responded and accepted to participate in the study. Due to the variability in time-to-event reporting across different centers, survival and relapse-related outcomes were analyzed descriptively. Continuous variables were summarized using medians and ranges, and categorical variables were described by counts and percentages. The association between individual baseline variables and patient survival, was conducted using a univariate analysis utilizing the chi-square test. Categorical variables such as patient and transplant characteristics were compared against survival status at last follow-up. All variables were further evaluated in the multivariate analysis. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier survival analysis. Between 2012 and 2024, a total of 673 patients received haplo-HSCT across ten centers, in six EMBMT-registered countries. Median age was 25 years, and the predominant indication for haplo-HSCT was leukemia (64.3%). Transplant was done using stem cells collected from peripheral blood in majority of cases (65.7%), and Total Body Irradiation (TBI) was utilized in 37.6% of all patient. 76.5% had malignant hematological disorders, while 23.5% had non-malignant disorders. Relapse was reported in 232 patients (34.5%) and death in 220 patients (32.7%). Of these, 88 deaths (12.8%) were attributed to disease progression. Haplo-HSCT activity increased steadily over the study period, with a marked increase in the last few years, reflecting broader regional adoption. PFS was 66% and 60% at 1- and 2- years after transplantation. Also, the 1-year and 2-year post-transplant OS was 71% and 65%, respectively. Multivariate analysis identified disease type and chronic GVHD as factors associated with improved outcomes. Despite variability across centers, outcomes were consistent with international benchmarks, underscoring the growing feasibility and therapeutic value of haplo-HSCT in the EMRO region. Haplo-HSCT is increasingly adopted across the EMRO region as the primary alternative donor HSCT modality. Our findings confirm its clinical efficacy, with outcomes comparable to international benchmarks. These results underscore the importance of continued regional collaboration and the development of personalized strategies to address challenges such as graft-versus-host disease (GVHD), disease relapse, and disparities in access to transplantation services.
- 1 April 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (6) , 668-676
Twelve-year utilization and outcomes of haploidentical hematopoietic stem cell transplantation (HSCT) in the Eastern Mediterranean (EM) region: A multicenter EMBMT registry analysis
Haploidentical hematopoietic stem cell transplant (Haplo-HSCT) has emerged as an alternative for patients lacking matched human leukocyte antigen (HLA) donors. The scarcity of stem cell donor registries and cord banks across the Eastern Mediterranean (EM) region has led to increased need of Haplo-HSCT as a mean to overcome this limitation. In this study, we aimed to assess trends in Haplo-HSCT utilization within the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) registry from 2012 to 2024, and describe key clinical and transplant-related factors associated with patient outcomes. We conducted a retrospective, multicenter registry-based analysis of patients who had their first un-manipulated Haplo-HSCT in ten EMBMT centers across six countries, who responded and accepted to participate in the study. Due to the variability in time-to-event reporting across different centers, survival and relapse-related outcomes were analyzed descriptively. Continuous variables were summarized using medians and ranges, and categorical variables were described by counts and percentages. The association between individual baseline variables and patient survival, was conducted using a univariate analysis utilizing the chi-square test. Categorical variables such as patient and transplant characteristics were compared against survival status at last follow-up. All variables were further evaluated in the multivariate analysis. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier survival analysis. Between 2012 and 2024, a total of 673 patients received haplo-HSCT across ten centers, in six EMBMT-registered countries. Median age was 25 years, and the predominant indication for haplo-HSCT was leukemia (64.3%). Transplant was done using stem cells collected from peripheral blood in majority of cases (65.7%), and Total Body Irradiation (TBI) was utilized in 37.6% of all patient. 76.5% had malignant hematological disorders, while 23.5% had non-malignant disorders. Relapse was reported in 232 patients (34.5%) and death in 220 patients (32.7%). Of these, 88 deaths (12.8%) were attributed to disease progression. Haplo-HSCT activity increased steadily over the study period, with a marked increase in the last few years, reflecting broader regional adoption. PFS was 66% and 60% at 1- and 2- years after transplantation. Also, the 1-year and 2-year post-transplant OS was 71% and 65%, respectively. Multivariate analysis identified disease type and chronic GVHD as factors associated with improved outcomes. Despite variability across centers, outcomes were consistent with international benchmarks, underscoring the growing feasibility and therapeutic value of haplo-HSCT in the EMRO region. Haplo-HSCT is increasingly adopted across the EMRO region as the primary alternative donor HSCT modality. Our findings confirm its clinical efficacy, with outcomes comparable to international benchmarks. These results underscore the importance of continued regional collaboration and the development of personalized strategies to address challenges such as graft-versus-host disease (GVHD), disease relapse, and disparities in access to transplantation services.
- Open Access
- 10 March 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Clinical practice guidelines for the diagnosis and management of Hodgkin lymphoma in countries with restricted resources
- 10 March 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Open AccessClinical practice guidelines for the diagnosis and management of Hodgkin lymphoma in countries with restricted resources
- 10 February 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (5) , e643-e653.e3
Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017
- 10 February 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (5) , e643-e653.e3
Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation With Survival Outcomes and Comparison to ELN 2017
- Open Access
- 17 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (1) , 30
Contraceptives in chronic lymphocytic leukemia (CLL): a narrative review
Women with chronic lymphocytic leukemia (CLL) face unique challenges when it comes to contraception. CLL predominantly affects older adults, with an age-adjusted incidence of approximately 4.7 new cases per 100,000 people per year and a median age at diagnosis of 70 years (Hallek and Al-Sawaf Am J Hematol 96(12):1679–1705, 2021). Although only about 9% of patients are diagnosed before age of 45, those who are of reproductive potential must carefully balance cancer treatment, fertility preservation, and effective contraception. In contemporary practice, most patients are treated with continuous Bruton’s tyrosine kinase (BTK) inhibitors or fixed-duration BCL2 inhibitor–based regimens, while chemoimmunotherapy is reserved for selected cases. These targeted approaches have variable profiles of cytopenias, bleeding and drug–drug interactions and can compromise ovarian reserve and carry teratogenic risks. This necessitates the need for tailored contraceptive counseling within a multidisciplinary oncofertility framework (Oktay et al J Clin Oncol 36(19):1994–2001, 2018).
- 17 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (1) , 30
Open AccessContraceptives in chronic lymphocytic leukemia (CLL): a narrative review
Women with chronic lymphocytic leukemia (CLL) face unique challenges when it comes to contraception. CLL predominantly affects older adults, with an age-adjusted incidence of approximately 4.7 new cases per 100,000 people per year and a median age at diagnosis of 70 years (Hallek and Al-Sawaf Am J Hematol 96(12):1679–1705, 2021). Although only about 9% of patients are diagnosed before age of 45, those who are of reproductive potential must carefully balance cancer treatment, fertility preservation, and effective contraception. In contemporary practice, most patients are treated with continuous Bruton’s tyrosine kinase (BTK) inhibitors or fixed-duration BCL2 inhibitor–based regimens, while chemoimmunotherapy is reserved for selected cases. These targeted approaches have variable profiles of cytopenias, bleeding and drug–drug interactions and can compromise ovarian reserve and carry teratogenic risks. This necessitates the need for tailored contraceptive counseling within a multidisciplinary oncofertility framework (Oktay et al J Clin Oncol 36(19):1994–2001, 2018).
- 6 January 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (5) , 720-726
Cutaneous T-cell lymphoma in Kuwait: a retrospective analysis of treatment modalities and prognostic factors
Background Cutaneous T-cell lymphoma (CTCL) is a rare malignancy with limited data available from the Middle East. This study evaluated the clinical characteristics, treatment patterns, and outcomes of CTCL patients treated in Kuwait. Methods This was a retrospective review of all adult patients diagnosed between February 2021 and March 2024. Data included demographics, staging, treatment modalities, and outcomes. Kaplan–Meier analysis was used to evaluate progression-free survival (PFS) and overall survival (OS). Results The study included 86 patients. The mean age at diagnosis was 44 years (range: 16–80), and 84% of patients presented with early-stage disease (IA–IIA). NB-UVB phototherapy was the most common treatment for early-stage disease, while brentuximab vedotin was frequently used for advanced diseases. Median OS was 30 months in patients with advanced disease and not reached in those with early-stage disease (p = 0.003). Median PFS was 22 months overall, and significantly longer in early-stage than advanced disease (50 vs. 15 months, p = 0.009). Advanced stage, blood involvement, and elevated LDH were significant predictors of worse PFS. Conclusion This study provides the first real-world analysis of CTCL outcomes in Kuwait. The findings underscore the importance of early detection and the role of novel therapies in disease management.
- 6 January 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 123 (5) , 720-726
Cutaneous T-cell lymphoma in Kuwait: a retrospective analysis of treatment modalities and prognostic factors
Background Cutaneous T-cell lymphoma (CTCL) is a rare malignancy with limited data available from the Middle East. This study evaluated the clinical characteristics, treatment patterns, and outcomes of CTCL patients treated in Kuwait. Methods This was a retrospective review of all adult patients diagnosed between February 2021 and March 2024. Data included demographics, staging, treatment modalities, and outcomes. Kaplan–Meier analysis was used to evaluate progression-free survival (PFS) and overall survival (OS). Results The study included 86 patients. The mean age at diagnosis was 44 years (range: 16–80), and 84% of patients presented with early-stage disease (IA–IIA). NB-UVB phototherapy was the most common treatment for early-stage disease, while brentuximab vedotin was frequently used for advanced diseases. Median OS was 30 months in patients with advanced disease and not reached in those with early-stage disease (p = 0.003). Median PFS was 22 months overall, and significantly longer in early-stage than advanced disease (50 vs. 15 months, p = 0.009). Advanced stage, blood involvement, and elevated LDH were significant predictors of worse PFS. Conclusion This study provides the first real-world analysis of CTCL outcomes in Kuwait. The findings underscore the importance of early detection and the role of novel therapies in disease management.
- Open Access
- 23 April 2025
- Published by MDPI AG in Hematology Reports
- Vol. 17 (3) , 22
Management of Diffuse Large B-Cell Lymphoma as Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report
Background and Clinical Significance: Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of solid organ transplantation, often associated with prolonged immunosuppression. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype. Managing PTLD requires a balance between reducing immunosuppression and preventing graft rejection. Case Presentation: A 41-year-old female kidney transplant recipient developed PTLD eight years post-transplant, presenting with a right submandibular mass. Biopsy confirmed CD20-positive DLBCL. Initial treatment involved reducing immunosuppression and rituximab monotherapy, which failed to prevent disease progression. The patient underwent six cycles of R-CHOP chemotherapy, achieving complete metabolic remission. Relapse occurred twice, with disease progression in the cervical nodes and tonsils. Salvage therapies, including polatuzumab vedotin and rituximab, achieved remission. During a subsequent relapse, loncastuximab tesirine induced metabolic resolution. Compromised renal function limited treatment options and a second renal transplant was delayed, reducing the risk of PTLD recurrence. Conclusions: This case underscores the challenges of managing PTLD in transplant recipients, especially in relapsed/refractory cases. Single-agent rituximab was insufficient, but combination chemotherapy and novel agents like loncastuximab tesirine were effective. Balancing oncologic control and graft preservation remains critical. This case highlights the need for individualized approaches and novel therapies in managing PTLD while addressing the complexities of immunosuppression and organ preservation.
- 23 April 2025
- Published by MDPI AG in Hematology Reports
- Vol. 17 (3) , 22
Open AccessManagement of Diffuse Large B-Cell Lymphoma as Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report
Background and Clinical Significance: Post-transplant lymphoproliferative disorder (PTLD) is a severe complication of solid organ transplantation, often associated with prolonged immunosuppression. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype. Managing PTLD requires a balance between reducing immunosuppression and preventing graft rejection. Case Presentation: A 41-year-old female kidney transplant recipient developed PTLD eight years post-transplant, presenting with a right submandibular mass. Biopsy confirmed CD20-positive DLBCL. Initial treatment involved reducing immunosuppression and rituximab monotherapy, which failed to prevent disease progression. The patient underwent six cycles of R-CHOP chemotherapy, achieving complete metabolic remission. Relapse occurred twice, with disease progression in the cervical nodes and tonsils. Salvage therapies, including polatuzumab vedotin and rituximab, achieved remission. During a subsequent relapse, loncastuximab tesirine induced metabolic resolution. Compromised renal function limited treatment options and a second renal transplant was delayed, reducing the risk of PTLD recurrence. Conclusions: This case underscores the challenges of managing PTLD in transplant recipients, especially in relapsed/refractory cases. Single-agent rituximab was insufficient, but combination chemotherapy and novel agents like loncastuximab tesirine were effective. Balancing oncologic control and graft preservation remains critical. This case highlights the need for individualized approaches and novel therapies in managing PTLD while addressing the complexities of immunosuppression and organ preservation.